-
Sulforaphane, ROS, and NLRP3 in Ulcerative Colitis
2026-09-01
A 2024 study in Biomedicine & Pharmacotherapy shows that sulforaphane reduces dextran sodium sulfate-induced colitis in mice while suppressing oxidative stress and NLRP3 inflammasome signaling. The work connects reactive oxygen species with inflammatory cytokine release and provides a useful framework for mechanistic inflammation studies, while remaining preclinical.
-
Amt-1 Activates Nrf2/HO-1 Against Influenza A
2026-08-31
The reference study identifies Amt-1, an adamantane-2,5-dihydroxy-benzylalcohol derivative, as a dual-action influenza A virus inhibitor that combines residual M2 ion-channel interaction with Nrf2/HO-1-mediated control of inflammation. Its activity in cell and mouse models suggests a host-directed strategy for addressing antiviral resistance and virus-induced lung injury, although additional pharmacological and translational studies are needed.
-
Separating Growth Arrest from Cell Killing in Cancer Assays
2026-08-31
Hannah Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its central contribution is a response-analysis framework that distinguishes proliferative arrest from true cell killing, improving interpretation of in vitro drug studies and informing more rigorous assay design.
-
EdU Imaging Kits (488) in CRC Translation
2026-08-30
A mechanistic and translational perspective on using EdU-based S-phase DNA synthesis measurement to strengthen colorectal cancer research, including studies of the EIF4A3–circEIF2S2–miR-646–UHMK1 axis.
-
Ampicillin sodium for Reliable Assay Workflows
2026-08-29
Learn how Ampicillin sodium (SKU A2510) can support controlled antibacterial activity assays while preventing antibiotic-related confounding in cell viability, proliferation, and cytotoxicity workflows. The article connects mechanism, protocol parameters, resistance interpretation, and practical product-selection criteria to improve experimental comparability.
-
Esflurbiprofen and SERT–nNOS: Rapid Antidepressant Action
2026-08-28
The reference study identifies esflurbiprofen as a candidate fast-onset antidepressant through a screening strategy focused on the SERT–nNOS interaction in the dorsal raphe nucleus. Its combination of mBRET-based target discovery, stress-model pharmacology, resting-state fMRI, and mechanistic serotonin measurements links disruption of this complex with reduced autoreceptor feedback and improved depressive-like behaviors in mice.
-
Neurotensin: GPCR Trafficking & miRNA Workflows
2026-08-28
Use Neurotensin as a controlled Neurotensin receptor 1 activator to connect acute G protein-coupled receptor signaling with receptor recycling and miR-133α modulation. This practical guide combines cell-based assay design, peptide-handling controls, and an evidence-based strategy for managing fluorescence interference during complex sample analysis.
-
Protease Inhibitor Cocktail for Ferroptosis Assays
2026-08-28
Learn how an EDTA-free protease inhibitor cocktail preserves METTL17, mitochondrial proteins, and phosphorylation-sensitive signals during ferroptosis research. This practical guide covers dilution, cell-lysate workflows, co-immunoprecipitation, kinase assays, and troubleshooting for colorectal cancer models.
-
Annexin V-PE Reagent for CAR-T Cell Death Assays
2026-08-27
Use Annexin V-PE Reagent to distinguish early phosphatidylserine exposure from later membrane failure in CAR-T and apoptosis workflows. This guide connects rapid flow cytometry or microscopy readouts with CD38 binder optimization, while emphasizing controls, mixed-culture gating, and practical troubleshooting.
-
GKT137831: Dual Nox1/Nox4 Inhibitor Workflows
2026-08-26
GKT137831 provides a mechanistically focused way to test Nox1/Nox4-driven oxidative stress in vascular, fibrotic, and metabolic models. This workflow also shows how to connect upstream ROS control with ferroptosis-associated plasma membrane damage without overstating the current evidence.
-
CHIR 99021 trihydrochloride in Organoid Workflows
2026-08-26
Use CHIR 99021 trihydrochloride as a tunable GSK-3 inhibitor to connect organoid expansion, lineage diversification, and pathway-specific assay design. This workflow translates recent human intestinal organoid findings into practical dosing, controls, troubleshooting, and metabolic research decisions.
-
Rotigotine Workflows for Dopamine Research
2026-08-26
Build more interpretable Parkinson’s disease research workflows with Rotigotine, from receptor-proximal cell assays to continuous-exposure animal models. This guide connects concentration selection, formulation control, neuroprotection readouts, and troubleshooting for a dopamine D2/D3 receptor agonist with broader dopaminergic activity.
-
Protease Inhibitor Cocktail EDTA-Free: K1010 Guide
2026-08-25
Protease Inhibitor Cocktail EDTA-Free K1010 is a 100X DMSO concentrate for broad protease control during protein extraction and sample preparation. Its EDTA-free formulation supports workflows that require divalent cations, including phosphorylation-sensitive and kinase assays, but it does not replace phosphatase inhibitors or assay-specific validation.
-
Protease Inhibitor Cocktail for OXPHOS Assays
2026-08-24
Discover how an EDTA-Free Protease Inhibitor can protect OXPHOS, LRPPRC, and signaling readouts from pre-analytical degradation. This guide connects inhibitor selection with Western blot, Co-IP, and cancer-metabolism assay design.
-
Protease Inhibitor Cocktail EDTA-Free: K1010
2026-08-24
Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) helps limit degradation of proteins during extraction and sample preparation while avoiding EDTA-related chelation. It is appropriate for lysates used in Western blotting, co-immunoprecipitation, pull-down, immunostaining, and phosphorylation-sensitive assays, but it should not be treated as a complete metalloprotease or phosphatase-control solution.